ClinicalTrials.gg
Active, not recruitingNCT06532331Updated Oct 6, 2026

A PhaseⅠStudy of ONO-7475 in Combination With ONO-4538 and Gemcitabine Plus Nab-paclitaxel (GnP), the Standard of Care, and ONO-7475 in Combination With GnP in Patients With Pancreatic Cancer

A Phase 1 interventional study of ONO-7475 and ONO-4538 in Metastatic Pancreatic Cancer, sponsored by Ono Pharmaceutical Co., Ltd.. Active, not recruiting at 9 sites in Japan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-06.

Sponsored by Ono Pharmaceutical Co., Ltd. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 7 months after the study started (first participant enrolled Dec 2023, registered Jul 2024).
Updated Oct 6, 2026Sponsor changed5 sites added+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
87
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 130 studies testing Albumin-Bound Paclitaxel in Pancreatic Neoplasms — 22 open to participants now, 33 under way, 4 of them phase 3. Albumin-Bound Paclitaxel · Pancreatic Neoplasms.

Planned enrollment
38th of 130
87 · median 47
Started
2023
with 7 others
Phase 1
30 of 130
none open now
Primary completion
2027-09
later than 24 of 32 live
Registered
122nd of 130
by date

Among the 130 studies testing Albumin-Bound Paclitaxel in Pancreatic Neoplasms, this one is the 38th largest by planned enrollment, is one of 8 that started in 2023, is one of 30 in phase 1, reaches primary completion later than 24 of the 32 other live ones, and was the 122nd registered.

Pancreatic Neoplasms

3,902 studies on the registry are indexed under Pancreatic Neoplasms; 1,004 are open to participants now.

Browse Pancreatic Neoplasms studies →

Open to participants now

22 of the 130 studies testing Albumin-Bound Paclitaxel in Pancreatic Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

17 more — sign in →

By country, each count listing its studies:

All 22 open studies →

About Albumin-Bound Paclitaxel

Albumin-Bound Paclitaxel: first FDA approval 2005 (ABRAXANE), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 741 Pancreatic Neoplasms studies recruiting now, 475 (64%) set no upper age limit and 152 (21%) stop at 75 or younger; 40 take children under 18; 60 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 130 studies testing Albumin-Bound Paclitaxel in Pancreatic Neoplasms, or all of them as a file.
02

Study summary

This study is PhaseⅠstudy to examine tolerability and safety of ONO-7475 in combination with ONO-4538 and gemcitabine plus nab-paclitaxel (GnP), the standard of care, and safety of ONO-7475 in combination with GnP in patients with metastatic pancreatic cancer as first-line treatment

03

Conditions studied

  • Metastatic Pancreatic Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patient with pancreatic cancer
  2. Patients have an performance status of 0 to 1
  3. Patients with a of at least 6 months

Exclusion criteria

Exclusion Criteria:

  1. Patients are unable to swallow oral medications
  2. Patients with severe complication
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
87 participants (estimated)

Study arms

  • Experimental
    ONO-7475+GnP

    Drug: ONO-7475 · Drug: Nab-paclitaxel · Drug: Gemcitabine

  • Experimental
    ONO-7475+ONO-4538+GnP

    Drug: ONO-7475 · Drug: ONO-4538 · Drug: Nab-paclitaxel · Drug: Gemcitabine

Interventions

  • Specified dose on specified days

  • Specified dose on specified days

    Also known as: Nivolumab

  • Specified dose on specified days

  • Specified dose on specified days

06

What researchers measure

Primary outcomes

  1. Dose-limiting toxicities (DLT)

    Time frame: 28 days

  2. Adverse event (AE)

    Time frame: Up to 28 days after the last dose

Secondary outcomes

  1. Pharmacokinetics (Plasma concentration of ONO-7475)

    Time frame: Up to Cycle16

  2. Pharmacokinetics (Plasma concentration of ONO-4538)

    Time frame: Through study completion, an average of 6 months

  3. Anti-ONO-4538 antibody

    Time frame: Through study completion, an average of 6 months

  4. Objective Response Rate (ORR)

    Time frame: Through study completion, an average of 6 months

  5. Disease Control Rate (DCR)

    Time frame: Through study completion, an average of 6 months

  6. Overall Survival (OS)

    Time frame: Through study completion, an average of 1 year

  7. Progression-Free Survival (PFS)

    Time frame: Through study completion, an average of 6 months

  8. Duration of Response (DOR)

    Time frame: Through study completion, an average of 6 months

  9. Time to Response (TTR)

    Time frame: Through study completion, an average of 6 months

  10. Best Overall Response (BOR)

    Time frame: Through study completion, an average of 6 months

  11. Percent change in the sum diameters of the target lesions

    Time frame: Through study completion, an average of 6 months

  12. Maximum percent change in the sum diameters of the target lesions

    Time frame: Through study completion, an average of 6 months

  13. CEA

    Time frame: Through study completion, an average of 6 months

  14. CA19-9

    Time frame: Through study completion, an average of 6 months

07

Study locations

9 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2023 (actual). Primary completion is estimated for Sep 2027, 45 months after the start.

Of 172 industry-sponsored phase 1 interventional studies under Pancreatic Neoplasms, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 62. This study's planned 45 months is close to that.

Counting every sponsor, half of 381 studies reached it within 45 months; a quarter within 32 and three quarters within 68.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 28, 2024
First posted
Aug 1, 2024
StartActual
Dec 6, 2023
Primary completionEst.
Sep 30, 2027
CompletionEst.
Mar 31, 2028
Last update
Oct 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
5 sites added, 5 sites removed
Show 5 added (5 Japan)
  • Aichi Cancer Center · Nagoya, Japan
  • Kanazawa University Hospital · Kanazawa, Japan
  • Kanagawa Cancer Center · Yokohama, Japan
  • Osaka International Cancer Institute · Osaka, Japan
  • Seirei Hamamatsu General Hospital · Hamamatsu, Japan
Show 5 removed
  • Aichi Cancer Center · Nagoya-shi, Japan
  • Kanazawa University Hospital · Kanazawa-shi, Japan
  • Kanagawa Cancer Center · Yokohama-shi, Japan
  • Osaka International Cancer Institute · Osaka-shi, Japan
  • Seirei Hamamatsu General Hospital · Hamamatsu-shi, Japan
Oct 6, 2026
Sponsor
Ono Pharmaceutical Co. Ltd→Ono Pharmaceutical Co., Ltd.
Oct 6, 2026
Show all 1 update
  1. Oct 6, 2026
    5 sites added, 5 sites removed
    Show 5 added (5 Japan)
    • Aichi Cancer Center · Nagoya, Japan
    • Kanazawa University Hospital · Kanazawa, Japan
    • Kanagawa Cancer Center · Yokohama, Japan
    • Osaka International Cancer Institute · Osaka, Japan
    • Seirei Hamamatsu General Hospital · Hamamatsu, Japan
    Show 5 removed
    • Aichi Cancer Center · Nagoya-shi, Japan
    • Kanazawa University Hospital · Kanazawa-shi, Japan
    • Kanagawa Cancer Center · Yokohama-shi, Japan
    • Osaka International Cancer Institute · Osaka-shi, Japan
    • Seirei Hamamatsu General Hospital · Hamamatsu-shi, Japan
    Sponsor Ono Pharmaceutical Co. Ltd→Ono Pharmaceutical Co., Ltd.
    + 4 other changes: identifiers, verification date, contact details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06532331
Responsible party
Sponsor
First posted
Aug 1, 2024
Start date
Dec 6, 2023
Primary completion
Sep 30, 2027 (estimated)
Completion
Mar 31, 2028 (estimated)
Last update
Oct 6, 2026

Study contacts

Project Leader
study director · Ono Pharmaceutical Co., Ltd.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Tamnorzatinib · Albumin-Bound Paclitaxel · Gemcitabine

Start the discussion